SG10202012791TA - Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof - Google Patents

Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof

Info

Publication number
SG10202012791TA
SG10202012791TA SG10202012791TA SG10202012791TA SG10202012791TA SG 10202012791T A SG10202012791T A SG 10202012791TA SG 10202012791T A SG10202012791T A SG 10202012791TA SG 10202012791T A SG10202012791T A SG 10202012791TA SG 10202012791T A SG10202012791T A SG 10202012791TA
Authority
SG
Singapore
Prior art keywords
hydroxypyridine
chlorophenyl
carbonyl
amino
compositions
Prior art date
Application number
SG10202012791TA
Inventor
James Copp
Ann NEWMAN
Anne Luong
Original Assignee
Akebia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akebia Therapeutics Inc filed Critical Akebia Therapeutics Inc
Publication of SG10202012791TA publication Critical patent/SG10202012791TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/803—Processes of preparation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
SG10202012791TA 2013-11-15 2014-11-14 Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof SG10202012791TA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361904803P 2013-11-15 2013-11-15

Publications (1)

Publication Number Publication Date
SG10202012791TA true SG10202012791TA (en) 2021-01-28

Family

ID=53058045

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202012791TA SG10202012791TA (en) 2013-11-15 2014-11-14 Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
SG10201803862UA SG10201803862UA (en) 2013-11-15 2014-11-14 Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201803862UA SG10201803862UA (en) 2013-11-15 2014-11-14 Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof

Country Status (24)

Country Link
US (7) US9701636B2 (en)
EP (2) EP3578546A1 (en)
JP (4) JP2016537365A (en)
KR (2) KR102495018B1 (en)
CN (2) CN114890943A (en)
AR (1) AR099354A1 (en)
AU (4) AU2014348523B2 (en)
BR (1) BR112016011065B1 (en)
CA (1) CA2930128A1 (en)
CL (1) CL2016001150A1 (en)
CR (2) CR20200220A (en)
DO (1) DOP2016000109A (en)
IL (2) IL245634A0 (en)
MA (1) MA39033A1 (en)
MX (3) MX2021001169A (en)
MY (1) MY180626A (en)
PE (1) PE20160945A1 (en)
PH (1) PH12016500866A1 (en)
RU (2) RU2016123382A (en)
SA (1) SA516371129B1 (en)
SG (2) SG10202012791TA (en)
TW (4) TWI665190B (en)
WO (1) WO2015073779A1 (en)
ZA (2) ZA201603189B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3357911T (en) * 2006-06-26 2022-08-10 Akebia Therapeutics Inc. Prolyl hydroxylase inhibitors and methods of use
NO2686520T3 (en) 2011-06-06 2018-03-17
CA3151685A1 (en) 2013-06-13 2014-12-18 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
KR102495018B1 (en) * 2013-11-15 2023-02-06 아케비아 테라퓨틱스 인코포레이티드 Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
JP2017503835A (en) * 2014-01-23 2017-02-02 アケビア セラピューティクス インコーポレイテッドＡｋｅｂｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． Compositions and methods for the treatment of ocular diseases
WO2016118858A1 (en) * 2015-01-23 2016-07-28 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
SI3277270T1 (en) 2015-04-01 2022-04-29 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
CN105837502A (en) * 2016-04-05 2016-08-10 湖南欧亚生物有限公司 Synthesis method of Vadadustat
WO2018108101A1 (en) 2016-12-13 2018-06-21 苏州科睿思制药有限公司 New crystal forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid and preparation method therefor
WO2019028150A1 (en) * 2017-08-01 2019-02-07 Akebia Therapeutics, Inc. Compositions for use in methods of treatment of hemoglobin disorders
CA3097219A1 (en) 2018-05-09 2019-11-14 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
WO2020075199A1 (en) 2018-10-12 2020-04-16 Mylan Laboratories Limited Polymorphic forms of vadadustat
EP3887356B1 (en) 2018-11-28 2023-08-02 Sandoz AG Multi-component crystals of an orally available hif prolyl hydroxylase inhibitor
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
IT202000014116A1 (en) 2020-06-12 2021-12-12 Olon Spa NEW CRYSTALLINE VADADUSTAT COMPOUND
WO2021257800A1 (en) * 2020-06-19 2021-12-23 Akebia Therapeutics, Inc. Modulation of drug-drug interactions of vadadustat
GB202011431D0 (en) * 2020-07-23 2020-09-09 Johnson Matthey Plc Polymorphs of vadadustat and methods for preparing the polymorphs
WO2022048613A1 (en) * 2020-09-04 2022-03-10 广东东阳光药业有限公司 Crystal form of hypoxia-inducible factor prolyl hydroxylase inhibitor and preparation method therefor
KR20230130035A (en) 2021-01-08 2023-09-11 아케비아 테라퓨틱스 인코포레이티드 Treatment methods using vadadustat
WO2022179967A1 (en) 2021-02-23 2022-09-01 Glaxosmithkline Intellectual Property (No.2) Limited Vadadustat for treating covid-19 in a hospitalized subject
US20240148707A1 (en) * 2021-03-01 2024-05-09 Akebia Therapeutics, Inc. Modulation of drug-drug interactions of vadadustat

Family Cites Families (194)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3894920A (en) 1971-12-21 1975-07-15 Sagami Chem Res Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives
US4016287A (en) 1972-07-17 1977-04-05 Boehringer Ingelheim Gmbh Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof
WO1990000882A1 (en) 1988-07-25 1990-02-08 Vsesojuzny Kurgansky Nauchny Tsentr 'vosstanovitelnaya Travmatologia I Ortopedia' Traction apparatus for restoring the shape of the hand
TW219933B (en) 1990-02-26 1994-02-01 Lilly Co Eli
US5405613A (en) 1991-12-11 1995-04-11 Creative Nutrition Canada Corp. Vitamin/mineral composition
TW352384B (en) 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
DE4219158A1 (en) 1992-06-11 1993-12-16 Thomae Gmbh Dr K Biphenyl derivatives, pharmaceutical compositions containing them and processes for their preparation
EP0650961B1 (en) 1993-11-02 1997-03-05 Hoechst Aktiengesellschaft Substituted heterocyclic carboxylic acid amides, their preparation, and their use as medicaments
DE59401923D1 (en) 1993-11-02 1997-04-10 Hoechst Ag Substituted heterocyclic carboxylic acid amide esters, their preparation and their use as medicaments
TW406076B (en) 1993-12-30 2000-09-21 Hoechst Ag Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
DE4410480A1 (en) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridine-2-carboxylic acid ester amides and their pyridine N-oxides, processes for their preparation and their use as medicaments
DE4410423A1 (en) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carboxamides and their pyridine N-oxides, processes for their preparation and their use as medicaments
IL135495A (en) 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of substituted quinoline-2-carboxylic acid amides
JPH09221476A (en) 1995-12-15 1997-08-26 Otsuka Pharmaceut Co Ltd Medicinal composition
JP2000509047A (en) 1996-04-30 2000-07-18 ヘキスト・アクチエンゲゼルシヤフト 3-Alkoxypyridine-2-carboxamide esters, their preparation and their use as medicaments
DE19620041A1 (en) 1996-05-17 1998-01-29 Merck Patent Gmbh Adhesion receptor antagonists
DE19650215A1 (en) 1996-12-04 1998-06-10 Hoechst Ag 3-hydroxypyridine-2-carboxylic acid amide esters, their preparation and their use as medicaments
US6420427B1 (en) 1997-10-09 2002-07-16 Ono Pharmaceutical Co., Ltd. Aminobutyric acid derivatives
DE19746287A1 (en) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituted isoquinoline-2-carboxylic acid amides, their preparation and their use as medicaments
DE69919349T2 (en) 1998-03-23 2005-01-13 Aventis Pharmaceuticals Inc. PIPERIDINYL AND N-AMIDINOPIPERIDINYL DERIVATIVES
PT1107974E (en) 1998-08-27 2006-10-31 Teva Pharma NEW FORMS OF SODIUM ALENDRONATE HYDRATES, PROCESSES FOR THEIR PRODUCTION AND THEIR PHARMACEUTICAL COMPOSITIONS
US6500987B1 (en) 1998-11-27 2002-12-31 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs
EP1133459B1 (en) 1998-11-27 2006-01-11 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride form v
US6159379A (en) 1999-05-04 2000-12-12 Baker Hughes Incorporated Organic ammonium salts for the removal of water soluble organics in produced water
JP2001048786A (en) 1999-08-05 2001-02-20 Yamanouchi Pharmaceut Co Ltd Tricyclic heteroaryl derivative
CA2379322A1 (en) 1999-08-11 2001-02-15 Teva Pharmaceutical Industries Ltd. Torsemide polymorphs
ATE288893T1 (en) 1999-11-17 2005-02-15 Teva Pharma POLYMORPHOUS FORM OF ATORVASTATIN CALCIUM
AU779306B2 (en) 1999-12-14 2005-01-13 Teva Gyogyszergyar Reszvenytarsasag Novel forms of pravastatin sodium
EP1254146B1 (en) 1999-12-16 2005-08-24 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin polymorphs and novel polymorph iv
WO2001043742A1 (en) 1999-12-16 2001-06-21 Teva Pharmaceuticals Industries Ltd. Novel processes for making- and a new crystalline form of- leflunomide
SK8872002A3 (en) 1999-12-21 2002-12-03 Teva Pharma Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them
CZ20022332A3 (en) * 2000-01-07 2003-01-15 Transform Pharmaceuticals, Inc. Sample assembly
PL356645A1 (en) 2000-01-11 2004-06-28 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin polymorphs
US6589758B1 (en) 2000-05-19 2003-07-08 Amgen Inc. Crystal of a kinase-ligand complex and methods of use
DK1309547T3 (en) 2000-07-27 2007-05-21 Teva Pharma Crystalline and pure modafinil and process for making the same
US20020183553A1 (en) 2000-10-19 2002-12-05 Ben-Zion Dolitzky Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
CZ20031298A3 (en) 2000-10-19 2003-10-15 Teva Pharmaceutical Industries Ltd. Process for preparing venlafaxine crystalline base and novel venlafaxine hydrochloride polymorphs
YU32003A (en) 2000-10-30 2006-05-25 Teva Pharmaceutical Industries Ltd. Novel crystal and solvate forms of ondansteron hydrochloride and processes for their preparation
CN1535139A (en) 2000-11-03 2004-10-06 ������ҩ��ҵ���޹�˾ Atorvastatin hemi-calcium form VII
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
AU2002250057A1 (en) 2001-02-12 2002-08-28 Teva Pharmaceutical Industries Ltd. New crystal forms of oxcarbazepine and processes for their preparation
US6849718B2 (en) 2001-03-20 2005-02-01 Dana Farber Cancer Institute, Inc. Muteins of hypoxia inducible factor alpha and methods of use thereof
US6855510B2 (en) 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
US20040146964A1 (en) 2001-03-21 2004-07-29 Maxwell Patrick Henry Assays, methods and means
PL366576A1 (en) 2001-04-09 2005-02-07 Teva Pharmaceutical Industries Ltd. Polymorphs of fexofenadine hydrochloride
SE0101327D0 (en) 2001-04-12 2001-04-12 Astrazeneca Ab New crystalline forms
US6852858B2 (en) 2001-08-01 2005-02-08 Biogal Gyogyszergyar Rt. Process for purifying N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide (zaleplon) and crystalline forms of zaleplon accessible with the process
US6849736B2 (en) 2001-09-07 2005-02-01 Teva Pharmaceutical Industries Ltd. Crystalline forms of valacyclovir hydrochloride
PT1451194E (en) 2001-10-03 2007-01-31 Teva Pharma Preparation of levofloxacin hemihydrate
US6566088B1 (en) 2001-10-04 2003-05-20 Board Of Regents, The University Of Texas System Prolyl-4-hydroxylases
GB0124941D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
EP1453509A2 (en) 2001-11-08 2004-09-08 Teva Pharmaceutical Industries Ltd. Polymorphs of fexofenadine base
ES2234451T1 (en) 2001-11-14 2005-07-01 Teva Pharmaceutical Industries Ltd. CRYSTAL FORMS AND AMORPHES OF LOSARTAN POTASIO AND PROCEDURE FOR PREPARATION.
EP1470116A4 (en) 2001-12-04 2005-04-06 Biogal Gyogyszergyar Preparation of orlistat and orlistat crystalline forms
EP2324834B1 (en) 2001-12-06 2019-05-08 Fibrogen, Inc. Methods of Increasing Endogenous Erythropoietin (EPO)
ES2316650T3 (en) 2001-12-18 2009-04-16 Teva Pharmaceutical Industries Ltd. CLOPIDOGREL HYDROGENOSULPHATE POLYMORPHES.
PL371263A1 (en) 2001-12-28 2005-06-13 Biogal Gyogyszergyar Rt Processes for preparing crystalline and amorphous mupirocin calcium
JP2005515226A (en) 2002-01-15 2005-05-26 テバ ファーマシューティカル インダストリーズ リミティド Crystalline solids of carvedilol and methods for preparing them
JP2005519076A (en) 2002-02-15 2005-06-30 テバ ファーマシューティカル インダストリーズ リミティド Novel crystalline form of atorvastatin hemi-calcium and process for its preparation and novel process for preparing atorvastatin hemi-calcium Form I, VIII and IX
US20030216376A1 (en) 2002-03-20 2003-11-20 Revital Lifshitz-Liron Crystalline forms of quetiapine hemifumarate
CA2480352A1 (en) 2002-03-27 2003-10-09 Teva Pharmaceutical Industries Ltd. Lansoprazole polymorphs and processes for preparation thereof
MXPA04010009A (en) 2002-04-11 2005-07-01 Teva Pharma Novel polymorphs and pseudopolymorphs of risedronate sodium.
US6897340B2 (en) 2002-04-29 2005-05-24 Teva Pharmaceutical Industries Ltd. Processes for preparation of polymorphic form II of sertraline hydrochloride
JP2005529908A (en) 2002-04-30 2005-10-06 テバ ジョジセルジャール レースベニュタールシャシャーグ Novel crystalline form of ondansetron, process for producing the same, pharmaceutical composition containing the novel form, and method of treating nausea using the composition
JP2005534633A (en) 2002-05-10 2005-11-17 テバ ファーマシューティカル インダストリーズ リミティド A new crystal form of gatifloxacin
WO2003105851A1 (en) 2002-06-01 2003-12-24 Teva Pharmaceuticals Industries Ltd. Novel crystalline forms of gatifloxacin
ES2239554T1 (en) 2002-06-10 2005-10-01 Teva Pharmaceutical Industries Ltd. FORM XVI FEXOFENADINE HYDROCLORIDE POLYMORPHIC.
US7534913B2 (en) 2002-07-18 2009-05-19 Teva Pharmaceutica Industries Ltd. Crystalline form of nateglinide
JP2006511614A (en) 2002-07-18 2006-04-06 テバ ファーマシューティカル インダストリーズ リミティド Polymorphic shape of nateglinide
US20040022764A1 (en) * 2002-07-31 2004-02-05 Hanan Polansky Inhibition of microcompetition with a foreign polynucleotide as treatment of chronic disease
US7396839B2 (en) 2002-08-06 2008-07-08 Teva Pharmaceuticals Usa, Inc. Crystalline forms of gatifloxacin
US20040097528A1 (en) 2002-08-26 2004-05-20 Ben-Zion Dolitzky Crystalline solid famciclovir forms I, II, III and preparation thereof
US20050043329A1 (en) 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
CA2508871C (en) 2002-11-28 2008-09-09 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
EP1485097A1 (en) 2002-12-12 2004-12-15 Teva Pharmaceutical Industries Limited Crystalline forms of gatifloxacin and processes for preparation
EP1575962A1 (en) 2002-12-24 2005-09-21 Teva Pharmaceutical Industries Limited Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
CA2518999A1 (en) 2003-03-12 2004-09-23 Teva Pharmaceutical Industries Ltd Crystalline and amorphous solids of pantoprazole and processes for their preparation
ES2232331T1 (en) 2003-03-12 2005-06-01 Biogal Gyogyszergyar Rt. PROCEDURES FOR THE PREPARATION OF DESLORATADINE POLYMORPHIC FORMS.
CA2519490A1 (en) 2003-03-17 2004-09-30 Teva Pharmaceutical Industries Ltd Polymorphis of valsartan
WO2004103999A1 (en) 2003-05-15 2004-12-02 TEVA Gyógyszergyár Részvénytársaság AZTREONAM β POLYMORPH WITH VERY LOW RESIDUAL SOLVENT CONTENT
EP1638972A2 (en) 2003-06-02 2006-03-29 Teva Pharmaceutical Industries Limited Novel crystalline forms of valacyclovir hydrochloride
EP1530570A2 (en) 2003-06-03 2005-05-18 Teva Pharmaceutical Industries Limited CRISTALLINE ZIPRASIDONE HCl AND PROCESSES FOR PREPARATION THEREOF
DK1644336T3 (en) 2003-06-06 2011-05-09 Fibrogen Inc Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
US7368468B2 (en) 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them
GB0314129D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
JP2007524619A (en) 2003-06-18 2007-08-30 テバ ファーマシューティカル インダストリーズ リミティド Fluvastatin sodium crystalline form, process for its preparation, composition containing it, and use thereof
US20050054616A1 (en) 2003-07-03 2005-03-10 Judith Aronhime Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation
CA2546701C (en) 2003-11-24 2010-07-27 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
EP1594493A2 (en) 2003-12-16 2005-11-16 Teva Pharmaceutical Industries Ltd. Polymorphic forms of tegaserod base and salts thereof
CA2550726A1 (en) 2003-12-16 2005-06-30 Teva Pharmaceutical Industries Ltd. Methods of preparing aripiprazole crystalline forms
CN1934108A (en) 2003-12-18 2007-03-21 特瓦制药工业有限公司 Polymorphic form B2 of ziprasidone base
EP1708708A1 (en) 2004-01-30 2006-10-11 Teva Pharmaceutical Industries Ltd. Montelukast free acid polymorphs
CA2554789A1 (en) 2004-01-30 2005-08-18 Teva Pharmaceutical Industries, Ltd. Montelukast sodium polymorphs
CA2555294A1 (en) 2004-02-11 2005-08-25 Marina Yu Etinger Candesartan cilexetil polymorphs
JPWO2005108370A1 (en) 2004-04-16 2008-03-21 味の素株式会社 Benzene compounds
CA2560882A1 (en) 2004-04-26 2005-11-03 Teva Pharmaceutical Industries Ltd. Crystalline forms of fexofenadine hydrochloride and processes for their preparation
JP2007528858A (en) 2004-05-07 2007-10-18 テバ ファーマシューティカル インダストリーズ リミティド Polymorphic form of nateglinide
JP2007538087A (en) 2004-05-18 2007-12-27 テバ ファーマシューティカル インダストリーズ リミティド Drying process for preparing crystalline solid famciclovir
JP2006528203A (en) 2004-05-20 2006-12-14 テバ ファーマシューティカル ファイン ケミカルズ ソチエタ レスポンサビリタ リミテ Levalbuterol hydrochloride polymorph A
MX2007000087A (en) 2004-06-23 2007-11-06 Teva Pharma Solid and crystalline ibandronic acid.
JP2007504173A (en) 2004-06-29 2007-03-01 テバ ファーマシューティカル インダストリーズ リミティド Linezolid type IV crystals
CA2576307A1 (en) 2004-07-01 2006-03-09 Teva Pharmaceutical Industries Ltd. Crystalline forms of 1,24(s)-dihydroxy vitamin d2
WO2006012379A2 (en) 2004-07-20 2006-02-02 Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg Processes for preparation of crystalline mycophenolate sodium
WO2006020348A2 (en) 2004-07-22 2006-02-23 Teva Pharmaceutical Fine Chemicals S.R.L. Polymorphs of atomoxetine hydrochloride
CA2575243A1 (en) 2004-07-22 2006-02-02 Teva Pharmaceutical Industries Ltd. Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation
EP1713489B1 (en) 2004-08-23 2011-01-19 Teva Pharmaceutical Industries Ltd Crystalline form of ibandronate sodium and processes for preparation thereof
US20060154957A1 (en) 2004-09-21 2006-07-13 Nina Finkelstein Crystalline clopidogrel hydrobromide and processes for preparation thereof
WO2006037042A1 (en) 2004-09-28 2006-04-06 Teva Pharmaceutical Industries Ltd. Fexofenadine crystal form and processes for its preparation thereof
EP1799216A2 (en) 2004-11-02 2007-06-27 Teva Pharmaceutical Industries Ltd Tadalafil crystal forms and processes for preparing them
EP1807400A2 (en) 2004-11-03 2007-07-18 Teva Pharmaceutical Industries, Inc. Amorphous and polymorphic forms of telmisartan sodium
WO2006055964A2 (en) 2004-11-19 2006-05-26 Teva Pharmaceutical Industries Ltd. Zolmitriptan crystal forms
JP2007519757A (en) 2004-12-01 2007-07-19 テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ Preparation method of pimecrolimus
WO2006060808A1 (en) 2004-12-03 2006-06-08 Teva Pharmaceutical Industries Ltd. Ezetimibe polymorphs
PT1836157E (en) 2005-01-11 2009-11-24 Teva Pharm Fine Chemicals Srl Process for the preparation of 1-amino-3,5-dimethyladamantane hydrochloride
WO2006081515A2 (en) 2005-01-27 2006-08-03 Teva Pharmaceutical Industries Ltd. Duloxetine hydrochloride polymorphs
WO2006084210A2 (en) 2005-02-04 2006-08-10 Regents Of The University Of California, San Diego Hif modulating compounds and methods of use thereof
CA2602073A1 (en) 2005-02-24 2006-08-31 Teva Pharmaceutical Industries Ltd. Processes for the preparation of linezolid intermediate
JP2008531571A (en) 2005-02-24 2008-08-14 テバ ファーマシューティカル インダストリーズ リミティド Radostidyl tartrate crystals, process for producing the same, and pharmaceutical composition
MX2007010931A (en) 2005-03-08 2007-10-16 Teva Pharma Crystal forms of (s)-(+)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2- thienyl) propanamine oxalate and the preparation thereof.
US20060270684A1 (en) 2005-03-14 2006-11-30 Judith Aronhime Crystalline forms of ziprasidone mesylate
CN101160281A (en) 2005-04-06 2008-04-09 特瓦制药工业有限公司 Crystalline forms of pregabalin
DE102005019712A1 (en) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone and its use
EP1975150A1 (en) 2005-05-23 2008-10-01 Teva Pharmaceutical Industries Ltd. Cinacalcet salts
MX2007014632A (en) 2005-05-23 2008-01-24 Cadbury Adams Usa Llc Taste potentiator compositions and edible confectionery and chewing gum products containing same.
WO2006133391A2 (en) 2005-06-06 2006-12-14 Fibrogen, Inc. Improved treatment for anemia using a hif-alpha stabilising agent
WO2006135757A1 (en) 2005-06-09 2006-12-21 Teva Pharmaceutical Industries Ltd. Crystalline forms of carvedilol and processes for their preparation
US20070100165A1 (en) 2005-06-09 2007-05-03 Ronen Borochovitz Process for preparation of sertraline hydrochloride form I
US8530404B2 (en) 2005-06-15 2013-09-10 Fibrogen, Inc. Compounds and methods for treatment of cancer
MX2007002113A (en) 2005-06-22 2007-04-27 Teva Pharma Polymorphic forms of tegaserod maleate.
US20070154482A1 (en) 2005-09-12 2007-07-05 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
WO2007038571A2 (en) 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
WO2007038676A2 (en) 2005-09-28 2007-04-05 Teva Pharmaceutical Industries Ltd. Polymorphic forms of ladostigil tartrate
WO2007047194A2 (en) 2005-10-11 2007-04-26 Dana-Farber Cancer Institute, Inc. Methods for treating mitf-related disorders
KR101440982B1 (en) 2005-10-19 2014-09-17 테바 파마슈티컬 인더스트리즈 리미티드 Crystals of laquinimod sodium, and process for the manufacture thereof
JP2008525531A (en) 2005-10-31 2008-07-17 テバ ファーマシューティカル インダストリーズ リミティド Crystalline form of cefdinir potassium salt
EP1828208A2 (en) 2005-10-31 2007-09-05 Teva Pharmaceutical Industries Ltd Crystalline form of cefdinir cesium salt
WO2007059307A2 (en) 2005-11-15 2007-05-24 Teva Pharmaceutical Industries Ltd. Crystalline and amorphous forms of telithromycin
EP1828098A1 (en) 2005-11-22 2007-09-05 Teva Pharmaceutical Industries Ltd Crystal forms of cinacalcet hci and processes for their preparation
WO2007070359A2 (en) 2005-12-09 2007-06-21 Amgen Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof
KR20100023059A (en) 2005-12-13 2010-03-03 테바 파마슈티컬 인더스트리즈 리미티드 Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
WO2007081890A2 (en) 2006-01-05 2007-07-19 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Production of dolasetron
WO2007081835A2 (en) 2006-01-09 2007-07-19 Btg International Limited Modulators of hypoxia inducible factor-1 and related uses
WO2007082899A1 (en) 2006-01-17 2007-07-26 Vib Vzw Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
US20070208072A1 (en) 2006-01-18 2007-09-06 Gustavo Frenkel Maleate salt of tegaserod and crystalline forms thereof
JP4801451B2 (en) 2006-01-19 2011-10-26 株式会社日立ハイテクノロジーズ Control device and control method for electron gun used in scanning electron microscope and the like
US20070208053A1 (en) 2006-01-19 2007-09-06 Arnold Lee D Fused heterobicyclic kinase inhibitors
ITMI20060179A1 (en) 2006-02-02 2007-08-03 Abiogen Pharma Spa PROCEDURE FOR RESOLUTION OF RACEMIC MIXTURES AND DIASTEREOISOMERIC COMPLEX OF A SOLVING AGENT AND UNANTIOMER OF INTEREST
US20070293702A1 (en) 2006-02-21 2007-12-20 Viviana Braude Novel crystalline forms of armodafinil and preparation thereof
CA2642180A1 (en) 2006-02-27 2007-09-07 Teva Pharmaceutical Industries Ltd. Fluvastatin sodium novel forms and preparation therof
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
PE20071020A1 (en) 2006-03-07 2007-12-11 Smithkline Beecham Corp N-SUBSTITUTED GLYCINE DERIVATIVE COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS
WO2007109799A2 (en) 2006-03-23 2007-09-27 Teva Pharmaceutical Industries Ltd. Polymorphs of eszopiclone malate
JP2009537558A (en) 2006-05-16 2009-10-29 スミスクライン・ビーチャム・コーポレイション Prolyl hydroxylase inhibitor
TWI394747B (en) 2006-06-23 2013-05-01 Smithkline Beecham Corp Prolyl hydroxylase inhibitors
LT3357911T (en) 2006-06-26 2022-08-10 Akebia Therapeutics Inc. Prolyl hydroxylase inhibitors and methods of use
TW200845994A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: prolyl hydroxylase inhibitors
CL2008000066A1 (en) 2007-01-12 2008-08-01 Smithkline Beecham Corp COMPOUNDS DERIVED FROM (5-HYDROXY-3-OXO-2,3-DIHYDROPIRIDAZINE-4-CARBONYL) GLYCINE, HIFROXYLASE HYDROXYLASE HIF INHIBITORS; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE IN THE TREATMENT OF THE ANEM
US7569726B2 (en) 2007-04-18 2009-08-04 Amgen Inc. Indanone derivatives that inhibit prolyl hydroxylase
WO2008130527A1 (en) 2007-04-18 2008-10-30 Merck & Co., Inc. Novel 1,8-naphthyridine compounds
EP2150251B9 (en) 2007-05-04 2013-02-27 Amgen, Inc Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity
CN101678011B (en) 2007-05-16 2012-07-18 默沙东公司 Spiroindalones
TW200908984A (en) 2007-08-07 2009-03-01 Piramal Life Sciences Ltd Pyridyl derivatives, their preparation and use
CN101815718A (en) 2007-08-10 2010-08-25 克里斯捷诺米有限公司 Pyridine derivate and using method thereof
WO2009039323A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009039321A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009043093A1 (en) 2007-10-04 2009-04-09 Newsouth Innovations Pty Limited Hif inhibition
WO2009049112A1 (en) 2007-10-10 2009-04-16 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
CN101918444A (en) 2007-11-08 2010-12-15 健泰科生物技术公司 Anti-factor B antibodies and their uses
WO2009067790A1 (en) 2007-11-26 2009-06-04 Uti Limited Partnership STIMULATION OF HYPOXIA INDUCIBLE FACTOR -1 ALPHA (HIF-1α) FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE (CDAD), FOR INTESTINAL MOTILITY AND FOR DETECTING INFECTION
JP2011508725A (en) 2007-11-30 2011-03-17 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Prolyl hydroxylase inhibitor
CN101932324A (en) 2007-11-30 2010-12-29 葛兰素史密斯克莱有限责任公司 Prolyl hydroxylase inhibitors
WO2009073669A1 (en) 2007-12-03 2009-06-11 Fibrogen, Inc. Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions
WO2009086044A1 (en) 2007-12-19 2009-07-09 Smith Kline Beecham Corporation Prolyl hydroxylase inhibitors
US20110003013A1 (en) 2008-01-04 2011-01-06 Garvan Institute Of Medical Research Method of increasing metabolism
EP2252619B1 (en) 2008-01-11 2013-10-09 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
AR071997A1 (en) * 2008-06-04 2010-07-28 Bristol Myers Squibb Co CRYSTAL FORM OF 6 - ((4S) -2-METHYL-4- (2-NAFTIL) -1,2,3,4-TETRAHYDROISOQUINOLIN-7-IL) PIRIDAZIN-3-AMINA
NO2686520T3 (en) 2011-06-06 2018-03-17
AU2012268400C1 (en) 2011-06-06 2016-12-22 Akebia Therapeutics Inc. Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
EP2734504B1 (en) * 2011-07-22 2016-09-14 Beijing Betta Pharmaceuticals Co., Ltd Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof
US8772895B2 (en) 2011-11-28 2014-07-08 Taiwan Semiconductor Manufacturing Company, Ltd. Dark current reduction for back side illuminated image sensor
EP2637274B1 (en) 2012-03-05 2022-05-04 Vetco Gray Scandinavia AS Power cable termination arrangement
CA3151685A1 (en) 2013-06-13 2014-12-18 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
KR102495018B1 (en) 2013-11-15 2023-02-06 아케비아 테라퓨틱스 인코포레이티드 Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
JP2017503835A (en) 2014-01-23 2017-02-02 アケビア セラピューティクス インコーポレイテッドＡｋｅｂｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． Compositions and methods for the treatment of ocular diseases
WO2016118858A1 (en) 2015-01-23 2016-07-28 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
AU2016235534A1 (en) 2015-03-20 2017-10-12 Akebia Therapeutics, Inc. Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors
SI3277270T1 (en) 2015-04-01 2022-04-29 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
WO2018108101A1 (en) 2016-12-13 2018-06-21 苏州科睿思制药有限公司 New crystal forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid and preparation method therefor
CA3097219A1 (en) 2018-05-09 2019-11-14 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
WO2021087144A1 (en) 2019-10-31 2021-05-06 Akebia Therapeutics, Inc. Therapeutic methods using vadadustat
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid

Also Published As

Publication number Publication date
US20200345711A1 (en) 2020-11-05
AU2020294308B2 (en) 2022-08-11
SA516371129B1 (en) 2019-07-28
SG10201803862UA (en) 2018-06-28
MA39033A1 (en) 2017-11-30
KR102495018B1 (en) 2023-02-06
ZA201905255B (en) 2020-11-25
US20180280365A1 (en) 2018-10-04
MX2016006271A (en) 2017-05-04
US20150141467A1 (en) 2015-05-21
AU2019202144A1 (en) 2019-04-18
RU2016123382A (en) 2017-12-20
AU2014348523B2 (en) 2019-01-03
ZA201603189B (en) 2019-11-27
BR112016011065A2 (en) 2017-08-08
CL2016001150A1 (en) 2016-12-09
CN105916502A (en) 2016-08-31
JP2016537365A (en) 2016-12-01
RU2021125455A (en) 2021-10-05
BR112016011065A8 (en) 2020-04-22
CR20160222U (en) 2016-08-26
KR102381295B1 (en) 2022-03-31
NZ719970A (en) 2022-03-25
KR20160083118A (en) 2016-07-11
KR20220042498A (en) 2022-04-05
TWI788702B (en) 2023-01-01
US20170258773A1 (en) 2017-09-14
PE20160945A1 (en) 2016-09-26
EP3068394A1 (en) 2016-09-21
DOP2016000109A (en) 2016-08-31
PH12016500866A1 (en) 2016-06-20
CR20200220A (en) 2020-11-18
US10149842B2 (en) 2018-12-11
US20190290624A1 (en) 2019-09-26
TW202335670A (en) 2023-09-16
IL245634A0 (en) 2016-06-30
MY180626A (en) 2020-12-03
US10596158B2 (en) 2020-03-24
CN114890943A (en) 2022-08-12
NZ759132A (en) 2022-03-25
US20240122910A1 (en) 2024-04-18
JP2022176961A (en) 2022-11-30
MX2021001169A (en) 2023-02-10
US20220040159A1 (en) 2022-02-10
TWI665190B (en) 2019-07-11
WO2015073779A1 (en) 2015-05-21
IL281648A (en) 2021-05-31
AU2020294308A1 (en) 2021-02-18
TW202126300A (en) 2021-07-16
US11065237B2 (en) 2021-07-20
EP3578546A1 (en) 2019-12-11
MX2021007268A (en) 2021-07-15
AU2019202144B2 (en) 2020-10-08
US9987262B2 (en) 2018-06-05
EP3068394A4 (en) 2017-04-26
JP2020183408A (en) 2020-11-12
BR112016011065B1 (en) 2022-10-25
CA2930128A1 (en) 2015-05-21
AU2022259767A1 (en) 2022-12-01
TW201605801A (en) 2016-02-16
AU2014348523A1 (en) 2016-06-09
JP2019167353A (en) 2019-10-03
TW201946625A (en) 2019-12-16
US9701636B2 (en) 2017-07-11
US11690836B2 (en) 2023-07-04
AR099354A1 (en) 2016-07-20

Similar Documents

Publication Publication Date Title
IL281648A (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
IL261372A (en) Preparation, uses and solid forms of obeticholic acid
HUE038664T2 (en) C6-c18-acylated derivative of hyaluronic acid, method of preparation thereof, nanomicellar composition on its basis, method of preparation thereof and method of preparation stabilized nanomicellar composition, and use thereof
HUE041924T2 (en) Cosmetic composition based on hyaluronic acid, method of preparation and use thereof
HUE048666T2 (en) Agricultural endophyte-plant compositions, and methods of use
IL233503B (en) Isocitrate dehydrogenase inhibitors, compositions comprising same and uses thereof
EP3082819A4 (en) Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith
HK1215567A1 (en) Five-and-six-membered heterocyclic compound, and preparation method, pharmaceutical composition and use thereof
FI2699553T3 (en) Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
HK1247201A1 (en) Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
EP3021843A4 (en) Anti-viral compounds, pharmaceutical compositions, and methods of use thereof
HK1202415A1 (en) Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15- hetre and methods of use thereof dgla15-ohepa/ 15-hetre
EP3012256A4 (en) Benzimidazole-2-piperazine heterocyclic compound, pharmaceutical composition thereof, preparation method and use thereof
EP3049389A4 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
ZA201308268B (en) Herbicidal composition comprising pinoxaden and fluroxypyrester, and methods of use thereof
IL234825A0 (en) Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregation, compositions comprising same and uses thereof
HK1188791A1 (en) Novel octahydrothienoquinoline derivative, pharmaceutical composition comprising derivative, and use of these
EP3049077A4 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
IL246408A0 (en) Sustained release depot formulations of therapeutic proteins, and uses thereof
PL3074045T3 (en) Sprayable aqueous composition comprising glyceryl trinitrate
HK1217670A1 (en) Formulations of albu-bche, preparation and uses thereof albu-bche
ZA201704677B (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid,compositions,and uses thereof
TH0901001717A (en) Throstocytrid, amino acid composition, and methods of making and use thereof.